UNC Lineberger Comprehensive Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, UNC Lineberger Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#97 of 15,742 sponsors by registered trial count).
UNC Lineberger Comprehensive Cancer Center: 366 sponsored US clinical trials, 79 recruiting.
UNC Lineberger Comprehensive Cancer Center sponsors 366 registered US clinical trials on ClinicalTrials.gov, 79 of them currently recruiting, and 209 completed. 2 of these trials are in Phase 3-4 (later-stage) and 157 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 29 trials.
Top-decile sponsor footprint
UNC Lineberger Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#97 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
209 of 246 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
366 total, page 6 of 8
Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy
NCT02449837
The Impact of a Physical Activity Program on Biomarkers of Aging During Chemotherapy for Breast Cancer
NCT02167932
Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients
NCT02035787
Evaluation of the Lung Nodule Sensitivity of Stationary Chest Tomosynthesis in Patients With Known Lung Nodules
NCT02075320
Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
NCT02008058
Exercise and Quality of Life in Leukemia Patients
NCT02246907
The Use of Smart Scales for Weight Gain Prevention in African American Breast Cancer Survivors
NCT02030353
Improving Survivorship Care Through Enhanced Communication and Coordination: Pilot Study
NCT02111616
Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer
NCT02010567
Monitoring of Oral Human Papillomavirus Infection (HPV) in HPV-positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)
NCT02045186
Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer
NCT02139774
Radiation Adherence/Toxicity in Patients With Non-Ovarian Gynecological Cancers
NCT02003430
Pilot Study: Utilizing Manometry to Assess Radiation-Induced Changes in Esophageal Function
NCT01992068
Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib
NCT01875666
Single Arm on the Tolerability of Weekly Nab-paclitaxel
NCT01702844
Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors
NCT01859858
Evaluation of Cardiorespiratory Performance After Interval Exercise Training Prior to Hematopoietic Cell Transplantation
NCT02577939
Open-label Pilot Evaluating Renal Lesions w/ Contrast-enhaced US in Patients w/ Renal Cancer
NCT01751529
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
NCT01726738
Assessment of Ability of Breath Hold for Left-sided Breast Cancer Radiation Therapy to Reduce Side Effects to Heart
NCT01849614
PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)
NCT01800032
Metformin for the Treatment of Endometrial Hyperplasia
NCT01685762
Comparison of Stationary Breast Tomosynthesis and 2-D Digital Mammography in Patients With Known Breast Lesions
NCT01773850
Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
NCT01573702
Predicting Tolerance to Radiation Therapy in Older Adults With Cancer
NCT01752751
PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study
NCT01751516
Feasibility of an Evidence-based Walking Program in Cancer Pts 60+ During Chemotherapy
NCT01789983
Hybrid PET/MR in the Therapy of Cervical Cancer
NCT01759355
Imaging Correlates of Renal Cell Carcinoma Biological Features
NCT01665703
Positron Emission Tomography (PET) Study for Staging of Muscle Invasive Bladder Cancer
NCT01655745
Study of Outcomes After Surgery/Treatment to Treat Bladder Cancer
NCT01776138
Finding Predictors of Side Effects to Chemoradiation Treatment in Elderly Patients With Head and Neck Cancer
NCT01688323
Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction
NCT01578954
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
NCT01612351
Cardiovascular Risk and Preventive Care in Prostate Cancer Patients Receiving Radiation and Hormone Therapy
NCT02003417
Patient Preferences for Breast Reconstruction After Mastectomy
NCT01488357
BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer
NCT01571024
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
NCT01578967
De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca
NCT01530997
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT01412229
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212
NCT01467310
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
NCT01688336
Circulating Tumor Cells in Solid Tumors
NCT03161821
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
NCT01488487
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
NCT01305941
Development of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions
NCT01457196
Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer
NCT01300962
Neoadjuvant Pazopanib in Renal Cell Carcinoma
NCT01361113
Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects
NCT01323062
Preoperative Window Study of Metformin for the Treatment of Endometrial Cancer
NCT01911247
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 71 |
| Phase 2 | 86 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the UNC Lineberger Comprehensive Cancer Center pipeline
79 recruiting of 366 indexed (22% open); 209 completed (57%).
Phase mix: 2 late (III/IV) vs 157 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (29 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
UNC Lineberger Comprehensive Cancer Center: open-pipeline peers nationwide
Peers matched on 366 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
UNC Lineberger Comprehensive Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 366 trials (± recruiting share)
- Roswell Park Cancer Institute · 365 trials · 16% recruiting
- University of California, Irvine · 368 trials · 20% recruiting
- New York State Psychiatric Institute · 364 trials · 3% recruiting
- Northwell Health · 370 trials · 22% recruiting
Sponsors near 22% open enrollment (± trial volume)
- Women and Infants Hospital of Rhode Island · 22% recruiting · 65 trials
- Merck Sharp & Dohme · 22% recruiting · 558 trials
- Henry M. Jackson Foundation for the Advancement of Military Medicine · 22% recruiting · 60 trials
- AbbVie · 21% recruiting · 526 trials
Related
What to do with this UNC Lineberger Comprehensive Cancer Center page
366 registered trials is a research-attention snapshot, not an endorsement of UNC Lineberger Comprehensive Cancer Center or any single study.
- 79 of UNC Lineberger Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition UNC Lineberger Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
UNC Lineberger Comprehensive Cancer Center pipeline card: 366 registered trials from official public datasets.Report a data error.